Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2935-2942

  Dalton, R Neil ^a   Chetty, Raj ^b   Stuart, Mary ^b   Iacona, Renee B ^b   Swaisland, Alan ^b  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Creatinine; Renal function; Saracatinib

Indexed keywords

CREATININE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; INULIN CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; MALE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; BENZODIOXOLES; CREATININE; DOUBLE-BLIND METHOD; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SRC-FAMILY KINASES; YOUNG ADULT;

EID: 77955813918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358, 2003. (Pubitemid 36791891)
2. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 4: 470-480, 2004.
3. Irby RB and Yeatman TJ: Role of Src expression and activation in human cancer. Oncogene 19: 5636-5642, 2000.
4. Homsi J, Cubitt C and Daud A: The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11: 91-100, 2007. (Pubitemid 46099755)
5. Trevino JG, Summy JM and Gallick GE: SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6: 681-687, 2006.
6. Green MR: Targeting targeted therapy. N Engl J Med 350: 2191-2193, 2004.
7. Gallagher NJ, Lockton AJ, Macpherson M, Marshall A and Clack G: A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual specific Src-Ab1 kinase inhibitor. Proc Am Assoc Cancer Res 46: abst 3972, 2005.
8. Lansang MC, Stevanovic R, Price DA, Laffel LM and Hollenberg NK: ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney Int 67: 1033-1037, 2005. (Pubitemid 41623327)
9. National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. 2006. Available at: http.//ctep. cancer.gov. Last accessed on 5 May 2010.
10. Hottelart C, El Esper N, Rose F, Achard JM and Fournier A: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92: 536-541, 2002.
11. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J and for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009.
12. Preuss HG: Organic cationic drugs and renal creatinine secretion. Ren Physiol 6: 103, 1983.
13. Urakami Y, Kimura N, Okuda M and Inui K: Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21: 976-981, 2004. (Pubitemid 38870147)
14. Andreev E, Koopman M and Arisz L: A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246: 247-252, 1999.
15. Ansquer JC, Dalton RN, Causse E, Crimet D, Le MK and Foucher C: Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 51: 904-913, 2008. (Pubitemid 351697561)
16. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.